Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.86 USD | +0.38% | -2.19% | -14.50% |
May. 01 | HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 | MT |
May. 01 | Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.50% | 88.58B | |
+26.78% | 681B | |
+21.85% | 556B | |
-4.96% | 361B | |
+17.19% | 325B | |
+5.43% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-4.06% | 157B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Karyopharm, Bristol-Myers Squibb to Assess Mezigdomide With Selinexor for Relapsed, Refractory Multiple Myeloma